Terms: = Prostate cancer AND RHOA, ENSG00000067560, 387, ARHA, RhoA, RHOH12, RHO12, ARH12, Rho12 AND Clinical Outcome
3 results:
1. Elevated miR-615-3p Expression Predicts Adverse clinical outcome and Promotes Proliferation and Migration of prostate cancer Cells.
Laursen EB; Fredsøe J; Schmidt L; Strand SH; Kristensen H; Rasmussen AKI; Daugaard TF; Mouritzen P; Høyer S; Kristensen G; Stroomberg HV; Brasso K; Røder MA; Borre M; Sørensen KD
Am J Pathol; 2019 Dec; 189(12):2377-2388. PubMed ID: 31539518
[TBL] [Abstract] [Full Text] [Related]
2. Urotensin II receptor predicts the clinical outcome of prostate cancer patients and is involved in the regulation of motility of prostate adenocarcinoma cells.
Grieco P; Franco R; Bozzuto G; Toccacieli L; Sgambato A; Marra M; Zappavigna S; Migaldi M; Rossi G; Striano S; Marra L; Gallo L; Cittadini A; Botti G; Novellino E; Molinari A; Budillon A; Caraglia M
J Cell Biochem; 2011 Jan; 112(1):341-53. PubMed ID: 21080343
[TBL] [Abstract] [Full Text] [Related]
3. Serum HER2 extracellular domain predicts an aggressive clinical outcome and biological PSA response in hormone-independent prostate cancer patients treated with docetaxel.
Domingo-Domenech J; Fernandez PL; Filella X; Martinez-Fernandez A; Molina R; Fernandez E; Alcaraz A; Codony J; Gascon P; Mellado B
Ann Oncol; 2008 Feb; 19(2):269-75. PubMed ID: 17998285
[TBL] [Abstract] [Full Text] [Related]
